TNF Pharmaceuticals Bilan de santé
Santé financière contrôle des critères 5/6
TNF Pharmaceuticals has a total shareholder equity of $382.3K and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $26.4M and $26.0M respectively.
Informations clés
0%
Ratio d'endettement
US$0
Dette
Ratio de couverture des intérêts | n/a |
Argent liquide | US$13.07m |
Fonds propres | US$382.29k |
Total du passif | US$26.00m |
Total des actifs | US$26.38m |
Mises à jour récentes de la santé financière
Recent updates
We Think MyMD Pharmaceuticals (NASDAQ:MYMD) Needs To Drive Business Growth Carefully
Sep 01We're Keeping An Eye On MyMD Pharmaceuticals' (NASDAQ:MYMD) Cash Burn Rate
May 19MyMD Pharma receives grant from European patent office for Supera-CBD compound
Aug 30Oramed, MyMD surge on plans for early-stage oral COVID vaccine data release in Q3
Jul 08Companies Like MyMD Pharmaceuticals (NASDAQ:MYMD) Could Be Quite Risky
Apr 12MyMD Pharmaceuticals (NASDAQ:MYMD) Is In A Good Position To Deliver On Growth Plans
Aug 29Analyse de la situation financière
Passif à court terme: TNFA's short term assets ($14.4M) exceed its short term liabilities ($5.8M).
Passif à long terme: TNFA's short term assets ($14.4M) do not cover its long term liabilities ($20.2M).
Historique et analyse du ratio d'endettement
Niveau d'endettement: TNFA is debt free.
Réduire la dette: TNFA currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Bilan
Analyse des pistes de trésorerie
Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.
Piste de trésorerie stable: TNFA has sufficient cash runway for more than a year based on its current free cash flow.
Prévisions de trésorerie: TNFA has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 10.2% each year.